Federated Hermes, Inc. X4 Pharmaceuticals, Inc Transaction History

Federated Hermes, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.88 - $1.91 $133 - $290	-152 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$1.48 - $2.58 $224 - $392	152 New	152 $1,000
Q4 2020 Feb 12, 2021	SELL	$5.41 - $7.4 $378 - $518	-70 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$6.09 - $9.15 $231 - $347	-38 Reduced 35.19%	70 $1,000
Q2 2020 Aug 13, 2020	BUY	$7.98 - $10.44 $861 - $1,127	108 New	108 $1,000

Q1 2020 May 13, 2020	SELL	$6.03 - $11.01 $6 - $11	-1 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$9.93 - $14.33 $9 - $14	1 New	1 $1,000
Q2 2019 Aug 14, 2019	SELL	$12.57 - $21.67 $861,887 - $1.49 Million	-68,567 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$15.19 - $22.98 $1.04 Million - $1.58 Million	68,567 New	68,567 $1.19 Million

106

103M

206K

291K

Ticker XFOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,646,096
Market Cap $39.8M
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.